Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor Vaccine Following Chemotherapy in Metastatic Breast Cancer
NCT00048893Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Nov 2002
- Primary completion
- Jun 2011
- Modality
- Viral Vector Vaccines, Oncolytic Viruses, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant fowlpox-CEA(6D)/TRICOM, recombinant vaccinia-CEA(6D)-TRICOM vaccine in breast cancer, sponsored by National Cancer Institute. Started Nov 2002; status: terminated.
02
Drugs
recombinant fowlpox-CEA(6D)/TRICOMrecombinant vaccinia-CEA(6D)-TRICOM vaccine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00048893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048893.